CureVac is a holding company. Through its subsidiaries, Co. is a biopharmaceutical company developing medicines based on messenger ribonucleic acid (mRNA). Co.'s product portfolio includes clinical and preclinical candidates in prophylactic vaccines, oncology and molecular therapy. In prophylactic vaccines, Co. is developing its mRNA vaccine candidate, CV2CoV against coronavirus (SARS-CoV-2) in collaboration with GlaxoSmithKline Biologicals SA. CV2CoV is a representative of its COVID-19 vaccine program. The vaccine candidate is a non-chemically modified mRNA, encoding the prefusion stabilized full-length spike protein of the SARS-CoV-2 virus, and formulated within Lipid Nanoparticles. The CVAC YTD return is shown above.
The YTD Return on the CVAC YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether CVAC YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the CVAC YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|